A new study shows the use of the anti-coagulant known as Pradaxa is associated with a significant increase in the risk of gastrointestinal bleeding. The increased risk is compared to traditional or standard treatment with drugs such as enoxaparin, warfarin, antiplatelet therapy, or no therapy (placebo).
The study analyzed 17 randomized controlled trails and found an increased risk for gastrointestinal bleeding for patients taking newer anti-coagulants versus the more traditional treatments. Although there was a ...
continue reading...